PathMaker is honored to be a finalist for BioChallenge 2026!

PathMaker’s clinical collaborators from BIDMC will present at the 2026 Annual NEALS meeting being held 10/27-10/30 in Clearwater, FL where they will discuss interim results from the CALM trial, funded by the DoD ALSRP program. Join us: meeting.neals.org/currentmee… #ALS #Neurotech

PathMaker announces selection as 1 of 6 companies to present at the BioChallenge competition on 10/29 in New Orleans. PathMaker looks forward to highlighting its clinical progress in developing the MyoRegulator as a non-invasive treatment for ALS. neworleansbio.com/biochallen… #ALS

PathMaker announces first study showing that its Multi-Site DCS technology can reduce toxic TDP-43 protein in ALS motor neurons. TDP-43 pathology is found in 97% of ALS cases, and stimulated mice showed a 76% reduction in TDP-43 particles. #ALS globenewswire.com/news-relea…

Nader Yaghoubi, M.D., Ph.D., Co-Founder and CEO, was a speaker at the MIT Health Science Technology Forum yesterday, where he highlighted PathMaker’s treatment for ALS. PathMaker thanks the MIT STEX and ILP for the opportunity! #MITSTEX #ModernTherapeutics #ALS #Neuromodulation

PathMaker has been selected to present at the MIT Health Science Technology Forum on 5/11. Dr. Nader Yaghoubi, Co-Founder/CEO, will be giving a talk on “Non-Invasive Treatment of ALS and Neurodegenerative Diseases using Neurotechnology”. More info: ilp.mit.edu/Health26 #ALS

Excited to join the disAbled Life Alliance Innovation Gateway! PathMaker is working to make ALS a livable disease by targeting motor neuron hyperexcitability and TDP-43 protein aggregation. Learn more: disabledlifealliance.com/dis… #ALS #MedTech #Neurotechnology #RareDisease

PathMaker is featured in this month's @RILifeSciHub newsletter! Grateful to grow alongside such a thriving life sciences ecosystem in Providence. #als #medtech #lifesciences myemail.constantcontact.com/…

At the MDA Conference this week, Dr. Nader Yaghoubi presented top-line results from the Company’s ALS Early Feasibility Study showing that treatment with the MyoRegulator device was safe/tolerable in ALS patients, with no unexpected changes on clinical endpoints. #MDAConference

PathMaker’s Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be speaking at the 2026 MDA Clinical & Scientific Conference being held March 8-11, 2026 in Orlando, Florida, where he will be discussing final results from PathMaker’s ALS EFS. Join us: mdaconference.org/

PathMaker Neurosystems would like to extend our congratulations to Board Director, John Donoghue, Ph.D., who has been named a 2026 Laureate of the Queen Elizabeth Prize for Engineering. Click to learn more: globenewswire.com/news-relea…

PathMaker announced today the completion of its ALS Early Feasibility Study (EFS) which evaluated the MyoRegulator® device as a non-invasive treatment for people with ALS and was supported by the Muscular Dystrophy Association (MDA). Read more: globenewswire.com/news-relea… #ALS

Nader Yaghoubi, M.D., Ph.D. from PathMaker Neurosystems and Seward Rutkove, M.D., Chair of the Department of Neurology at Beth Israel Deaconess Medical Center will be presenting at the NEALS Community Education Webinar this Friday, January 9 at 2 PM EST. #ALS #Neuromodulation

PathMaker is delighted to see that it has been included in the “Top 10 ALS News Stories of 2025” article by ALS News Today. We were the #4 story of 2025! Read the full article: alsnewstoday.com/news/top-10… #Neuromodulation #MedTech

Exciting News: PathMaker Neurosystems granted FDA Breakthrough Device Designation for MyoRegulator® neuromodulation device in ALS! Accelerates our path to market. Learn more: globenewswire.com/news-relea… #MedTech #Neuromodulation #ALS #EndALS

PathMaker’s breakthrough multi-site DCS technology can reduce toxic TDP-43 aggregates in neurons of ALS mice – broadening the applicability of this treatment to the large majority of ALS cases. Findings are being presented at the MNDA Symposium Dec 5-7 in San Diego🔥#ALS

PathMaker's Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be attending NEALS, a leading ALS conference being held October 8-10. PathMaker's clinical collaborators from BIDMC will be presenting a poster on their US Dept. of Defense-funded CALM trial.

Joining leaders at #ALSNexus 2025 in Dallas next week to dive into the latest ALS research, treatments & clinical progress! Excited to connect w/ leaders fighting for a cure. 💪Join the effort: event.alsnexus.org/event/beb… #EndALS

PathMaker Neurosystems’ non-invasive Multi-Site DCS technology shows tremendous potential in ALS treatment, as demonstrated by extended survival in a mouse model in Frontiers in Neurology. Read more: globenewswire.com/news-relea… #ALS #Neuromodulation